BioCentury
ARTICLE | Clinical News

Lampalizumab: Phase III started

September 22, 2014 7:00 AM UTC

Roche began the identical, double-blind, sham-controlled, international Phase III Chroma (GX29176) and Spectri (GX29185) trials to evaluate 10 mg intravitreal lampalizumab every 4 or 6 weeks each in 9...